ROS-scavenging nanomedicine for "multiple crosstalk" modulation in non-alcoholic fatty liver disease

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Pharmacology

Background:

• Non-alcoholic fatty liver disease (NAFLD) involves complex crosstalk of insulin resistance, lipid metabolism, and oxidative stress.
• Existing therapies face challenges due to oxidative stress-induced drug metabolism, impacting efficacy.
• Nanotechnology offers a promising approach to overcome these limitations through targeted delivery and ROS scavenging.

Purpose of the Study:

• To develop a ROS-responsive liposome (RLL) system for co-delivery of LY294002 and oridonin to treat NAFLD.
• To investigate the therapeutic efficacy of RLLs in regulating insulin resistance, lipid metabolism, and oxidative stress.
• To assess the potential of RLLs in overcoming drug metabolism issues caused by CYP3A11 activity in NAFLD.

Main Methods:

• Design and characterization of ROS-responsive liposomes (RLLs) loaded with LY294002 and oridonin.
• In vitro evaluation of particle size, zeta potential, ROS-responsive release, and ROS-scavenging properties.
• In vivo assessment using a CCl4-induced mouse model to evaluate biodistribution, therapeutic efficacy, and molecular mechanisms (Western blotting, ELISA, PCR).

Main Results:

• RLLs demonstrated good stability, biocompatibility, and effective ROS-scavenging capabilities.
• CD44-mediated targeting significantly enhanced RLL accumulation in the liver.
• RLL treatment in mice reduced oxidative stress, improved insulin sensitivity, normalized CYP450 activity, and alleviated inflammation and fibrosis.

Conclusions:

• The developed RLLs provide an effective nanotechnology-based strategy for NAFLD treatment.
• RLLs successfully deliver therapeutic agents while mitigating oxidative stress and improving metabolic profiles.
• This approach highlights the potential of ROS-responsive systems in enhancing drug efficacy for complex liver diseases.